Eohilia (budesonide oral suspension) — Highmark

Initial criteria

• age ≥ 11 years
• diagnosis of eosinophilic esophagitis (ICD-10: K20.0)
• esophageal biopsy showing eosinophil count ≥ 15 eos/hpf
• clinical symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, gastroesophageal reflux)
• therapeutic failure, contraindication, or intolerance to high-dose proton-pump inhibitor (PPI) therapy (e.g., omeprazole or pantoprazole 80 mg/day)

Reauthorization criteria

• Reauthorizations will not be approved as Eohilia has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks.

Approval duration

12 weeks